Cargando…
Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
BACKGROUND AND PURPOSE: Generation of cGMP via NO‐sensitive soluble guanylyl cyclase (sGC) has been implicated in the regulation of renal functions. Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem‐free form, ap...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292672/ https://www.ncbi.nlm.nih.gov/pubmed/34096053 http://dx.doi.org/10.1111/bph.15586 |
_version_ | 1784749427394609152 |
---|---|
author | Stehle, Daniel Xu, Min Ze Schomber, Tibor Hahn, Michael G. Schweda, Frank Feil, Susanne Kraehling, Jan R. Eitner, Frank Patzak, Andreas Sandner, Peter Feil, Robert Bénardeau, Agnès |
author_facet | Stehle, Daniel Xu, Min Ze Schomber, Tibor Hahn, Michael G. Schweda, Frank Feil, Susanne Kraehling, Jan R. Eitner, Frank Patzak, Andreas Sandner, Peter Feil, Robert Bénardeau, Agnès |
author_sort | Stehle, Daniel |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Generation of cGMP via NO‐sensitive soluble guanylyl cyclase (sGC) has been implicated in the regulation of renal functions. Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem‐free form, apo‐sGC. Apo‐sGC cannot be activated by NO, resulting in impaired cGMP signalling that is associated with chronic kidney disease progression. We hypothesised that sGC activators, which activate apo‐sGC independently of NO, increase renal cGMP production under conditions of oxidative stress, thereby improving renal blood flow (RBF) and kidney function. EXPERIMENTAL APPROACH: Two novel sGC activators, runcaciguat and BAY‐543, were tested on murine kidney. We measured cGMP levels in real time in kidney slices of cGMP sensor mice, vasodilation of pre‐constricted glomerular arterioles and RBF in isolated perfused kidneys. Experiments were performed at baseline conditions, under L‐NAME‐induced NO deficiency, and in the presence of oxidative stress induced by ODQ. KEY RESULTS: Mouse glomeruli showed NO‐induced cGMP increases. Under baseline conditions, sGC activator did not alter glomerular cGMP concentration or NO‐induced cGMP generation. In the presence of ODQ, NO‐induced glomerular cGMP signals were markedly reduced, whereas sGC activator induced strong cGMP increases. L‐NAME and ODQ pretreated isolated glomerular arterioles were strongly dilated by sGC activator. sGC activator also increased cGMP and RBF in ODQ‐perfused kidneys. CONCLUSION AND IMPLICATION: sGC activators increase glomerular cGMP, dilate glomerular arterioles and improve RBF under disease‐relevant oxidative stress conditions. Therefore, sGC activators represent a promising class of drugs for chronic kidney disease treatment. LINKED ARTICLES: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc |
format | Online Article Text |
id | pubmed-9292672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92926722022-07-20 Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney Stehle, Daniel Xu, Min Ze Schomber, Tibor Hahn, Michael G. Schweda, Frank Feil, Susanne Kraehling, Jan R. Eitner, Frank Patzak, Andreas Sandner, Peter Feil, Robert Bénardeau, Agnès Br J Pharmacol Cgmp Signalling in Cell Growth and Survival ‐ Research Papers BACKGROUND AND PURPOSE: Generation of cGMP via NO‐sensitive soluble guanylyl cyclase (sGC) has been implicated in the regulation of renal functions. Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem‐free form, apo‐sGC. Apo‐sGC cannot be activated by NO, resulting in impaired cGMP signalling that is associated with chronic kidney disease progression. We hypothesised that sGC activators, which activate apo‐sGC independently of NO, increase renal cGMP production under conditions of oxidative stress, thereby improving renal blood flow (RBF) and kidney function. EXPERIMENTAL APPROACH: Two novel sGC activators, runcaciguat and BAY‐543, were tested on murine kidney. We measured cGMP levels in real time in kidney slices of cGMP sensor mice, vasodilation of pre‐constricted glomerular arterioles and RBF in isolated perfused kidneys. Experiments were performed at baseline conditions, under L‐NAME‐induced NO deficiency, and in the presence of oxidative stress induced by ODQ. KEY RESULTS: Mouse glomeruli showed NO‐induced cGMP increases. Under baseline conditions, sGC activator did not alter glomerular cGMP concentration or NO‐induced cGMP generation. In the presence of ODQ, NO‐induced glomerular cGMP signals were markedly reduced, whereas sGC activator induced strong cGMP increases. L‐NAME and ODQ pretreated isolated glomerular arterioles were strongly dilated by sGC activator. sGC activator also increased cGMP and RBF in ODQ‐perfused kidneys. CONCLUSION AND IMPLICATION: sGC activators increase glomerular cGMP, dilate glomerular arterioles and improve RBF under disease‐relevant oxidative stress conditions. Therefore, sGC activators represent a promising class of drugs for chronic kidney disease treatment. LINKED ARTICLES: This article is part of a themed issue on cGMP Signalling in Cell Growth and Survival. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.11/issuetoc John Wiley and Sons Inc. 2021-07-03 2022-06 /pmc/articles/PMC9292672/ /pubmed/34096053 http://dx.doi.org/10.1111/bph.15586 Text en © 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Cgmp Signalling in Cell Growth and Survival ‐ Research Papers Stehle, Daniel Xu, Min Ze Schomber, Tibor Hahn, Michael G. Schweda, Frank Feil, Susanne Kraehling, Jan R. Eitner, Frank Patzak, Andreas Sandner, Peter Feil, Robert Bénardeau, Agnès Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney |
title | Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney |
title_full | Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney |
title_fullStr | Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney |
title_full_unstemmed | Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney |
title_short | Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney |
title_sort | novel soluble guanylyl cyclase activators increase glomerular cgmp, induce vasodilation and improve blood flow in the murine kidney |
topic | Cgmp Signalling in Cell Growth and Survival ‐ Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292672/ https://www.ncbi.nlm.nih.gov/pubmed/34096053 http://dx.doi.org/10.1111/bph.15586 |
work_keys_str_mv | AT stehledaniel novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT xuminze novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT schombertibor novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT hahnmichaelg novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT schwedafrank novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT feilsusanne novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT kraehlingjanr novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT eitnerfrank novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT patzakandreas novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT sandnerpeter novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT feilrobert novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney AT benardeauagnes novelsolubleguanylylcyclaseactivatorsincreaseglomerularcgmpinducevasodilationandimprovebloodflowinthemurinekidney |